Christian democracy

Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™

Retrieved on: 
Tuesday, September 21, 2021
Drink, Achievement, ROI, Cheese, Fatigue, Health, Immunity, Kirin Holdings, Functional food, Overalls, Frost & Sullivan, Lactococcus lactis, Christian democracy, Immune system, Immunology, The Non-GMO Project, PDC, Acquisition, NK, Leadership, GRAS, Kyowa Hakko Kirin, Yogurt, Research, Industry, Probiotic, Vaccine, Pharmaceutical industry

SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune health ingredient market, Frost & Sullivan recognizes Kyowa Hakko USA, Inc. (Kyowa Hakko) with the 2021 North American New Product Innovation Award for its clinically backed, patented, non-GMO, allergen-free paraprobiotic, IMMUSE™, Lactococcus lactis strain plasma (LC-Plasma),). The lactic acid bacteria developed by Kirin Holding Company Limited and offered by Kyowa Hakko USA, directly activates immune cells to provide comprehensive innate and adaptive immune support. IMMUSE™  provides ease of formulation and can be used in a number of products including drinks, yogurt, gummies and range of other functional food and beverages.

Key Points: 
  • The lactic acid bacteria developed by Kirin Holding Company Limitedand offered by Kyowa Hakko USA, directly activates immune cells to provide comprehensive innate and adaptive immune support.
  • Other immune support ingredients, including generic probiotics and beta-glucan, activate limited immune cell types, imparting only partial immune support compared to IMMUSE.
  • Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, led the development and product launch of IMMUSE notes, "IMMUSEis unlike any other immune support ingredient, by activating pDC's, key leaders of the immune system,IMMUSEprovides more comprehensive immune support."
  • It is an honor to have our innovative Kyowa Hakko clinically-studied ingredient recognized to elevate immune health products."

Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™

Retrieved on: 
Tuesday, September 21, 2021
Drink, Achievement, ROI, Cheese, Fatigue, Health, Immunity, Kirin Holdings, Functional food, Overalls, Frost & Sullivan, Lactococcus lactis, Christian democracy, Immune system, Immunology, The Non-GMO Project, PDC, Acquisition, NK, Leadership, GRAS, Kyowa Hakko Kirin, Yogurt, Research, Industry, Probiotic, Vaccine, Pharmaceutical industry

SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune health ingredient market, Frost & Sullivan recognizes Kyowa Hakko USA, Inc. (Kyowa Hakko) with the 2021 North American New Product Innovation Award for its clinically backed, patented, non-GMO, allergen-free paraprobiotic, IMMUSE™, Lactococcus lactis strain plasma (LC-Plasma),). The lactic acid bacteria developed by Kirin Holding Company Limited and offered by Kyowa Hakko USA, directly activates immune cells to provide comprehensive innate and adaptive immune support. IMMUSE™  provides ease of formulation and can be used in a number of products including drinks, yogurt, gummies and range of other functional food and beverages.

Key Points: 
  • The lactic acid bacteria developed by Kirin Holding Company Limitedand offered by Kyowa Hakko USA, directly activates immune cells to provide comprehensive innate and adaptive immune support.
  • Other immune support ingredients, including generic probiotics and beta-glucan, activate limited immune cell types, imparting only partial immune support compared to IMMUSE.
  • Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, led the development and product launch of IMMUSE notes, "IMMUSEis unlike any other immune support ingredient, by activating pDC's, key leaders of the immune system,IMMUSEprovides more comprehensive immune support."
  • It is an honor to have our innovative Kyowa Hakko clinically-studied ingredient recognized to elevate immune health products."

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Retrieved on: 
Wednesday, September 15, 2021
Drug discovery, U.S. Securities and Exchange Commission, Security (finance), FDA, PDC, Marketing, Patient, Company, Risk, LinkedIn, Safety, WM, Christian democracy, Exchange, List of life sciences, COVID-19, Twitter, Research, Cancer, News, Regulation, Part, Pharmaceutical industry

Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.

Key Points: 
  • Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.
  • The company is developing proprietary drugs independently and through research and development collaborations.
  • The WM study will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia

Retrieved on: 
Wednesday, August 18, 2021
Immunoglobulin M, Trial of the century, Endpoint security, Christian democracy, National, B cell, Research, Lymph, Safety, Risk, CLR, Bone marrow, Exchange, Lymphatic system, Fast track (FDA), ASCO, Orphan, Multiple myeloma, Drug discovery, Salvage therapy, ORR, LPL, PDC, CEO, National Institutes of Health, Twitter, 131, Incidence, Lymphoma, Tissue, Disease, Antibody, TFR, U.S. Securities and Exchange Commission, NASDAQ, Cytopenia, NCI, Waldenström's macroglobulinemia, SBIR, Haematopoietic system, LinkedIn, FDA, Macroglobulinemia, Security (finance), Rituximab, Lymphadenopathy, Cancer, Ibrutinib, GLOBE, End organ damage, Regulation, Prevalence, National Cancer Institute, News, NIH, COVID-19, NHL, Pharmaceutical industry

We appreciate the recognition and funding that the NIH and NCI have chosen to provide Cellectar for our pivotal iopofosine program.

Key Points: 
  • We appreciate the recognition and funding that the NIH and NCI have chosen to provide Cellectar for our pivotal iopofosine program.
  • This $2 million non-dilutive grant will be used to support and accelerate the ongoing pivotal study.
  • At ASCO this year, compelling iopofosine I-131 data were presented on six WM patients, which demonstrated a 100% overall response rate.
  • The pivotal study is designed as a global, non-comparator, single arm, expansion cohort of the currently ongoing Phase 2 CLOVER-1 study of iopofosine I-131.

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

Retrieved on: 
Monday, August 16, 2021
Trial of the century, NASDAQ, U.S. Securities and Exchange Commission, Regulation, Evergreen, CEO, News, WM, Company, PDC, LinkedIn, Christian democracy, Drug discovery, Phase 1, COVID-19, Twitter, USAN, GLOBE, Risk, GMP, Research, Exchange, FDA, Marketing, CDMO, Security (finance), Patient, Contract, Cancer, Safety, Part, Pharmaceutical industry, Medical device

FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has entered into a commercial manufacturing and supply agreement with Evergreen Theragnostics, a global radiopharmaceutical contract development and manufacturing organization (CDMO) based in Springfield, NJ. The company also announced that the United States Adopted Names Council (USAN) has approved the use of “iopofosine I-131” as the generic name for CLR-131.

Key Points: 
  • Evergreen will conduct process development and validation of additional large scale commercial quantities of iopofosine I-131 at its newly constructed, state-of-the-art manufacturing facility designed specifically for radiopharmaceutical manufacturing, including therapeutic and diagnostic radiopharmaceuticals.
  • James Cook, CEO of Evergreen Theragnostics stated that, We welcome this new collaboration with Cellectar Biosciences.
  • Iopofosine I-131 represents a unique and novel class of radiotherapeutics and Evergreen is excited to participate in its continued development and long-term supply to patients.
  • Evergreen Theragnostics, established in 2019, is a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO).

Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Retrieved on: 
Friday, August 13, 2021
Doxorubicin, Triple-negative breast cancer, NASDAQ, Agreement Respecting a New Relationship Between the Cree Nation and the Government of Quebec, MDR1, Clinical trial, Neutropenia, SEDAR, Docetaxel, Canadian Cancer Society, Cancer Science, PDC, Company, TSX, Tumor microenvironment, Senior, Survival, Cancer, Christian democracy, COVID-19, GLOBE, TNBC, Research, Ovary, FDA, Toxicity, Health, Skin, Mission statement, Consortium, Humanitarian use licenses, Lung, SORT1, Safety, Forward-looking statement, EDGAR, Peptide, Pharmaceutical industry, Fine chemical

The article is titled TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.

Key Points: 
  • The article is titled TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
  • Theratechnologies is currently developing a platform of new proprietary peptides for cancer drug development targeting SORT1 receptors called SORT1+ TechnologyTM.
  • It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development.
  • TH1902 is currently Theratechnologies lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology.

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

Retrieved on: 
Monday, August 9, 2021
Exchange, 131, U.S. Securities and Exchange Commission, Globe, Endpoint security, ORR, Society, Disease, Part, CLR, American Society of Clinical Oncology, COVID-19, FDA, GLOBE, CEO, TFR, Christian democracy, State Administrative Expenses, Cancer, Hematology, Mayo Clinic, Immunoglobulin M, WM, News, Regulation, Risk, NASDAQ, Clinical professor, ASCO, LinkedIn, Macroglobulinemia, Drug discovery, Cash, Safety, Marketing, MYD88, Poster, Development, Research, Therapy, Biotechnology, PDC, Insurance, Security (finance), PFS, Twitter, Pharmaceutical industry, Fine chemical, Medical device, Lithium

FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.
  • Median duration of response had not been reached, with 100% of the MYD88 wild type and high-risk patients exceeding 8.5 months.
  • During the second quarter, we remained focused on advancing both our preclinical and clinical objectives.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Cornerstone Building Brands Announces Completion of Debt Refinancing and Repayment of its $645 million, 8.00% Senior Notes

Retrieved on: 
Thursday, April 15, 2021
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Christian democracy, Stewardship

\xe2\x80\x9cWe have refinanced all of our credit facilities, meaningfully extending our debt maturities, while maintaining our covenant-lite structure.

Key Points: 
  • \xe2\x80\x9cWe have refinanced all of our credit facilities, meaningfully extending our debt maturities, while maintaining our covenant-lite structure.
  • Headquartered in Cary, North Carolina, the organization serves residential and commercial customers across new construction and repair and remodel markets.
  • At Cornerstone Building Brands, corporate stewardship is a responsibility that is deeply embedded in our over 75-year history.
  • We are committed to our purpose of contributing positively to the communities where we live, work and play.

South State Appoints First Director of Corporate Stewardship

Retrieved on: 
Wednesday, October 28, 2020
Banking, Professional services, Finance, Christian democracy, Stewardship

South State today announced it has appointed LeDon Jones its first director of Corporate Stewardship.

Key Points: 
  • South State today announced it has appointed LeDon Jones its first director of Corporate Stewardship.
  • View the full release here: https://www.businesswire.com/news/home/20201028005798/en/
    LeDon Jones has been named the Director of Corporate Stewardship for South State Bank.
  • South State has consistently earned top honors as an employer of choice and one of the best places to work.
  • By providing a dedicated focus on corporate stewardship, South State and the communities and organizations that we serve across the Southeast will grow and prosper together.

ChemDesign to Receive 2019 SOCMA Educational Outreach Award

Retrieved on: 
Tuesday, November 19, 2019
Christian democracy, Stewardship, Articles, Human behavior, Human activities, Society of Chemical Manufacturers and Affiliates

Educational Outreach is one of 29 Performance Improvement Awards that will be presented during SOCMA Week, December 4-6, in New Orleans.

Key Points: 
  • Educational Outreach is one of 29 Performance Improvement Awards that will be presented during SOCMA Week, December 4-6, in New Orleans.
  • For 13 years, SOCMA has honored facilities that are leading the charge in environmental stewardship and educational outreach.
  • "We commend ChemDesign and its outstanding team for going above and beyond to strengthen the future of specialties through education," said Joe Dettinger, Senior Director, Compliance & Stewardship.
  • We encourage other facilities to utilize ChemDesign as an example in growing their own educational outreach programs."